



Business and  
Professional  
Women/USA

**PUBLIC POLICY RESOLUTION**  
**Cancer Screening**  
**1**

WHEREAS, Business and Professional Women/USA (BPW/USA) supports insurance parity for women's health care needs; and

WHEREAS, BPW/USA recognizes the importance of increasing awareness regarding women's health; and

WHEREAS, ovarian cancer is the fifth leading cause of cancer death among women in the United States; and

WHEREAS, approximately 14,000 women died from ovarian cancer in the year 2001; and

WHEREAS, more women die of ovarian cancer each year than of cervical and endometrial cancers combined; and

WHEREAS, one of the ways to decrease the rate of deaths due to ovarian cancer is early screening and detection; and

WHEREAS, the CA-125 screening test is considered a reliable screening test when used in conjunction with transvaginal sonography and a rectovaginal pelvic exam; and

WHEREAS, the CA-125 is not covered routinely by insurance, is not administered routinely to female patients and is not widely known by female patients; and

WHEREAS, the PSA screening test for prostate cancer is covered routinely by insurance, is administered routinely to patients and is widely known by male patients; and therefore be it

RESOLVED that BPW/USA urges all state federations to work actively with their state legislators to introduce legislation requiring insurance companies to cover the CA-125 test; and therefore be it

RESOLVED FURTHER that BPW/USA will work with BPW members to educate women and physicians about the availability and benefits of the CA-125 test.

***Adopted July 2002***